APOA1 and type 2 diabetes mellitus: In summary, our findings for the apoA-I mimetic peptides adds to the growing evidence supporting a strong relationship between apoA-I and HDL treatments and reduced inflammation, insulin resistance and type 2 diabetes in mouse models.